PSMA PET/CT‐based PFS for patients with oligoprogressive prostate cancer treated with SBRT to all known sites of disease on PSMA PET/CT versus patients treated with 177Lu‐PNT2002 prior to SBRT to all known sites of disease. This evidence concerns the gene FOLH1 and Familial prostate cancer.